Search tips
ESCMID Global 2024
Courses & Events
Guidelines
From the archive: ECCMID and more before 2010
Search Results
Sort by:
Filter 0
Sort by
Filter
Sort by
Relevance
Date descending
Date ascending
30 April 2024 - P3982
Successful use of prolonged oral nirmatrelvir/ritonavir in an immunocompromised host with persistent SARS-CoV-2 viraemia and severe pneumonitis
Jessica Taylor
30 April 2024 - O1177
Oral zoliflodacin is non-inferior to a combination of ceftriaxone and azithromycin for treatment of uncomplicated urogenital gonorrhoea: results of a large global Phase III randomised controlled trial
Alison Luckey, Helen Broadhurst, Pierre Daram, Sinead Delany-Moretlwe, Henry J. C. De Vries, Rossaphorn Kittiyaowamarn, Drew Lewis, John P. Mueller, Seamus O'Brien, Mary-Ann Richardson, Subasree Srinivasan, Stephanie N. Taylor, Magnus Unemo, Edward W. Hook Rd
30 April 2024 - LB026
Pharmacokinetics and safety of the SARS-CoV-2 monoclonal antibody AZD3152 are consistent with those of tixagevimab/cilgavimab
Lindsay Clegg, Harjit Singh, Sam Matthews, Miles Avila, Huixia Zhang, Steven Thomas, Haitao Yang, Nicola Fawcett, Nora Philbin, Sambuddha Ghosh, Michael Gibbs, George Christou, Manish Shroff, Michael William, Rolando Viani, John L. Perez, Lee-Jah Chang, Taylor Cohen
30 April 2024 - LB029
Divergent performance of bivalent BA.5 and monovalent XBB.1.5 COVID-19 vaccines given as annual booster
Marianne Shawe-Taylor, David Greenwood, Agnieszka Hobbs, Giulia Dowgier, Rebecca Penn, Theo Sanderson, Phoebe Stevenson-Leggett, James Bazire, Ruth Harvey, George Kassiotis, Steve Gamblin, Nicola Lewis, Bryan Williams, Charles Swanton, Sonia Gandhi, Edward Carr, Mary Y. Wu, David L.V. Bauer, Emma Wall
30 April 2024 - LB023
B cell depletion therapy in people with multiple sclerosis impacts on antibody response to COVID-19 mRNA vaccines
Marianne Shawe-Taylor, David Greenwood, Anna He, Agnieszka Hobbs, Giulia Dowgier, Rebecca Penn, Theo Sanderson, Phoebe Stevenson-Leggett, James Bazire, Ruth Harvey, Dimitrios Champsas, Anuriti Aojula, Alessia Bianchi, Sarmad Al-Araji, Yael Hacohen, George Kassiotis, Steve Gamblin, Nicola Lewis, Bryan Williams, Charles Swanton, Sonia Gandhi, David L.V. Bauer, Mary Y. Wu, Edward Carr, Emma Wall, Olga Ciccarelli
29 April 2024 - P2977
Treatment outcomes with rezafungin and caspofungin in adults with invasive candidiasis and/or candidaemia who had received no prior antifungal therapy: ReSTORE trial subgroup analysis
George Thompson, Alex Soriano, Matteo Bassetti, Oliver A. Cornely, , Patrick M. Honore, Methee Chayakulkeeree, Taylor Sandison, Nick Manamley, Peter Pappas
29 April 2024 - P1650
First hospital trials of a new antimicrobial susceptibility test (AST) demonstrate accurate, cost-effective results from positive blood cultures in three hours
Daniel Spencer, Toby King, Hywel Morgan, Rhiannon Lyon, Isobel Taylor, Jade Conlon, Liz Sheridan, Mihye Lee, Philippa D'Arcy-Grover, Robert Impey, Maria Gatenby
28 April 2024 - P0890
Think sepsis? Think diagnostics and source identification
Frances Garraghan, Liz Craig, Jo Neumann-Taylor, Isra Halim, Kathryn Ashton
28 April 2024 - P0692
Evaluation of rapid molecular MTB/XDR assay in England: a low incidence drug resistant TB setting
Elena Ferran, Sarah Nalukenge, Jana Catalan-Riezu, Lucy Taylor, Vanessa Waite, Simon Warwick, Martin Dedicoat, Eliza Alexander, Esther Robinson
27 April 2024 - P0414
Prospects for reducing the risk of emergence of SARS-CoV-2 variants from infections in immunocompromised individuals: a modelling approach
Lisa J. White, Carla Talarico, Cátia Ferreira, Sylvia Taylor
27 April 2024 - P0381
High prevalence of immunocompromising conditions among patients with severe acute respiratory infection, including SARS-CoV-2: results from a multicentre, test-negative case-control study
Wilhelmine Meeraus, Ivana Prokić, Sudhir Venkatesan, Eduardo Conde-Sousa, Konstantina Chatzikonstantinidou, Sandra Manzanares Laya, Kaatje Bollaerts, Sylvia Taylor
27 April 2024 - P0382
Immunocompromise, cancer and other comorbidities in patients with severe acute respiratory infection testing positive versus negative for SARS-CoV-2: a post hoc analysis of COVIDRIVE data from May 2021 to May 2023
Wilhelmine Meeraus, Sudhir Venkatesan, Ivana Prokić, Eduardo Conde-Sousa, Konstantina Chatzikonstantinidou, Sandra Manzanares Laya, Sylvia Taylor, Kaatje Bollaerts
27 April 2024 - P0367
Sentinel cohort safety of AZD5156/AZD3152 from the phase 1/3 SUPERNOVA trial for COVID-19 prevention in participants with immune impairment
Rohini Beavon, Chris Webber, Steven Thomas, Lindsay Clegg, Nora Philbin, Mark Harre, Abdulhafez Selim, Taylor Cohen, John L. Perez
27 April 2024 - P0379
Serum AZD7442 (tixagevimab-cilgavimab) concentrations and in vitro IC50 values predict SARS-CoV-2 neutralising antibody (nAb) titres
Lindsay Clegg, Oleg Stepanov, Sam Matthews, Tom White, Seth Seegobin, Steven Thomas, Mats Någård, Mark Esser, Katie Streicher, Taylor Cohen, Anastasia Aksyuk
27 April 2024 - P0375
Effect of co-formulation on pharmacokinetics of AZD7442, a monoclonal antibody combination against COVID-19
Huixia Zhang, Roberta Baronio, Cecil Chi-Keung Chen, Samuel Sadow, Catherine Auge, Vitalina Dzutseva, Lauren Hirao, Antonella Nadia Tullio, Taylor Cohen, Michael Gibbs
27 April 2024 - P0409
Continued increased risk of COVID-19 hospitalisation and death in immunocompromised individuals despite receipt of ≥4 vaccine doses: updated 2023 results from INFORM, a retrospective health database study in England
Sabada Dube, Richard Mcnulty, Cátia Ferreira, Nahila Justo, Renata Yokota, Kathryn Evans, Lucy Carty, Mark Yates, Sylvia Taylor, Jennifer K. Quint, Rachael A. Evans
27 April 2024 - O0051
Individuals with multiple sclerosis are at high risk for COVID-19 hospitalisation and death despite high rates of vaccination: results from the England INFORM study
Lance Turtle, Sabada Dube, Richard Mcnulty, Cátia Ferreira, Nahila Justo, Renata Yokota, Kathryn Evans, Lucy Carty, Mark Yates, Jurgens Peters, Michelle Harley, Sylvia Taylor, Rachael A. Evans, Jennifer K. Quint
27 April 2024 - P0378
COVID-19 hospitalisations amongst immunocompromised individuals receiving 300 mg AZD7442 (tixagevimab/cilgavimab) pre-exposure prophylaxis: real-world effectiveness data from Israel's largest health maintenance organisation
Samah Hayek, Joseph Levy, Galit Shaham, Noa Dagan, Danielle Serby, Hadar Daskin-Bitan, Adva Yarden, Cátia Ferreira, Idit Livnat, Sabada Dube, Sylvia Taylor, Sudhir Venkatesan, Ran D. Balicer, Doron Netzer, Alon Peretz
27 April 2024 - P0237
Results from a large-scale dengue diagnostic accuracy systematic review and meta-analysis: NS1 ELISA performs similarly to RT-PCR
Kamla Pillay, Suzanne Keddie, Elizabeth Fitchett, Cassandra Akinde, Oliver Bärenbold, John Bradley, Jane Falconer, Ruth Keogh, Zhia Lim, Behrouz Nezafat Maldonado, Laura Maynard-Smith, Ellen Sugrue, Okuda Taylor, Heidi Hopkins, Audrey Dubot-Pérès
27 April 2024 - E0295
Identification of a protective neutralising antibody titre threshold for SARS-CoV-2 enabling rapid antibody development in response to evolving variants
Rhiannon Edge, Bahar Ahani, Anastasia A. Aksyuk, Lindsay Clegg, Sam Matthews, Mark T. Esser, Ian Hirsch, John Perez, John Pura, Oleg Stepanov, Katie Streicher, Tom White, Taylor Cohen, Dean Follmann, Peter B. Gilbert, Seth Seegobin
Loading ...
+ load more
FAQ
To access content in the Library you need to log in with your ESCMID member or user credentials. If you haven’t registered as an ESCMID member yet, then click here to do so – or use this link to register as a user.
The most recent event-related content is usually restricted to ESCMID members, while registered users get access one year after the event. However, there are events such as ESCMID Global where attendees get priority access, no matter if they are members or registered users. In these cases, we may offer non-attendees access after paying a fee.
You may search by event name, session title or number, topic title or number or author – or by any keyword. To get the most relevant results, enter the title or name in quotation marks, e.g. "Pre-ECCMID Day on Diagnostics" or "John Doe". If no quotation marks are used, then the exact result is shown first, followed by less exact results.
You may further narrow the number of search results for most terms by applying one or several filters, using the filter window on the start page. The Category and Media Type filters work for any content. In contrast, the Date from / to filter may not apply for Publications and Guidelines. In addition, the information text below a webcast or document offers the option of filtering search results by session title, author, event or category.
We defined four "hot topic" terms that you may search for by clicking the four tiles on the start page.
Linking two or more search terms by AND will show all results containing these search terms. For example, if you are looking for results that contain both the terms viral and hospital, then enter viral AND hospital.
Link two or more search terms by OR to get all results that contain at least one of these terms. For example, if you want to get results that contain either viral or infections or COVID, then enter viral OR infections OR COVID.
Place + in front of the term that you want to be included in your search result and place - in front of the term that you do not want to be included – without blanks in between in either case. For example, if you are aiming for search results that contain viral and infection but do not contain COVID, then enter +viral +infections -COVID.
A search term preceded by an exclamation point (no blanks in between) will lead to all content that does not contain the term, e.g. !COVID.
Deselect the ticked boxes in the filter dropdowns, click "Clear" on the calendars in the Date from / to filter – or refresh the website to remove all filters at once. Additionally, you may clear all applied filters by using the relevant buttons right above the search results.
No, as copyright protection limits the viewing of video presentations to web browsers, they cannot be downloaded.
No, due to our privacy policy we cannot disclose any contact details of persons involved.